<DOC>
	<DOCNO>NCT01288053</DOCNO>
	<brief_summary>Allogeneic transplantation high-risk procedure , although non-myeloablative conditioning regimen ( mini-transplantation ) minimize regimen related toxicity . The investigator , therefore , propose phase I study match sibling allogeneic hematopoietic stem cell transplantation non-myeloablative conditioning . In addition , graft versus host disease ( GVHD ) virtually eliminate CAMPATH remove donor T cell graft . The goal ass toxicity/efficacy ( phase I ) allogeneic non-myeloablative hematopoietic stem cell transplantation high-risk Crohn 's disease . In simplistic term , protocol design ablate aberrant immune system , similar use marrow transplant immunodeficient patient , reconstitute new immune system lymphocyte deplete marrow .</brief_summary>
	<brief_title>Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation ( NST ) Patients With Refractory Crohn 's Disease</brief_title>
	<detailed_description>PBSC mobilize G-CSF 10 mcg/kg/day ( dose may adjust 5 mcg/kg/day PI toxicity , e.g . flu-like symptom ) stem cell collection begin day 4 5 . Leukapheresis may repeat three consecutive day . Cyclophosphamide 60 mg/kg/day x 2 day give IV 1 hour 500 cc normal saline . Dosage base lesser adjust body weight actual weight . Mesna 50mg/day x 2 day give IV 24 hour CAMPATH-1H 30mg/day x 2 day ( dose adjustment ) give IV 2 hour 100 cc normal saline . Premedication Solumedrol 1g IV , Acetaminophen 650mg &amp; benadryl 50mg PO/IV give 30-60min infusion . Also CAMPATH , Chlorphenamine 4 mg PO TID , Singular 10 mg PO daily , Pepcid 40 mg PO BID Claritin 10 mg PO daily give , adjust need . These medication repeat change need . Fludarabine 30mg/m2 daily 3 day ( dose adjustment ) give IV 30 minute 100 cc normal saline . Hydration approximately 150ml/hr begin 2 hour cyclophosphamide continue 24 hour last cyclophosphamide dose . Daily weight obtain . Amount fluid modify base patient 's fluid status . G-CSF continue absolute neutrophil count reach least 1,000/ul . Cyclosporin start day -2 200 mg po BID adjust HPLC level 150 - 250 toxicity ( e.g. , tremor , renal insufficiency , TTP , etc. ) . CSA continue 30 day unless stop toxicity need maintain donor engraftment . Cyclosporine MMF guideline dosage duration modify accord investigator discretion base side effect , renal function , CBC GVHD status .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Patient eligibility 1 . Age &gt; 18 year less age 45 year time pretransplant evaluation , 2 . Ability give inform consent . And either A B A ) An establish clinical diagnosis severe CD disease onset 16 year old ( least 71 genetic locus predispose pediatric CD , Limbergen , JV . Annu . Rev . Genom . Human Genet . 2009 ; 10:89116 ) fail therapy prednisone , 5 ASA product fail antiTNF therapy . Failure define CDAI ( appendix A ) 250400 Craig Severity Score &gt; 17 ( appendix C ) . B ) Relapse autologous HSCT CDAI ( appendix A ) 250400 Craig Severity Score &gt; 17 ( appendix C ) . 1 . HIV positive . 2 . History coronary artery disease , congestive heart failure . 3 . Uncontrolled diabetes mellitus illness opinion investigator would jeopardize ability patient tolerate aggressive chemotherapy . 4 . Prior history malignancy except localize basal cell squamous skin cancer . Other malignancy patient judge cured local surgical therapy , head neck cancer , stage I breast cancer consider individual basis 5 . Positive pregnancy test , lactation , inability unwillingness pursue effective mean birth control , failure accept comprehend irreversible sterility side effect therapy . 6 . Psychiatric illness mental deficiency make compliance treatment inform consent impossible . 7 . FEV 1/FVC &lt; 50 % predict , DLCO &lt; 50 % predict . 8 . Resting LVEF &lt; 50 % . 9 . Bilirubin &gt; 2.0 mg/dl , transferase ( AST ) &gt; 2x upper limit normal , unless abnormality secondary Crohn 's disease . 10 . Serum creatinine &gt; 2.0 mg/dl . 11 . Platelet count less 100,000/ul , ANC le 1500/ul . 12 . Patients present intestinal perforation toxic megacolon , suppurative problem require urgent surgery . In addition , patient may active infection . The presence intestinal stoma exclude patient study . 13 . Prestudy peripheral blood count must include platelet count great 100,000/ul absolute neutrophil count great 1500/ul . 14 . Creatinine clearance 20 % low limit normal age sex . 15 . Short gut syndrome . Donor eligibility Inclusion criterion 1 . Donor must HLA 6 6 match sibling Exclusion criterion HLA match sibling donor 1 . Physiologic age &gt; 50 year old &lt; 18 year old 2 . HIV positive 3 . Active ischemic heart disease heart failure 4 . Acute chronic active hepatitis 5 . Uncontrolled diabetes mellitus illness opinion investigator would jeopardize ability donor tolerate stem cell collection 6 . Prior history malignancy except localize basal cell squamous skin cancer . Other malignancy patient judge cured local surgical therapy , ( limit ) head neck cancer , stage I II breast cancer consider individual basis . 7 . Positive pregnancy test 8 . Psychiatric illness mental deficiency make compliance treatment inform consent impossible 9 . Major hematological abnormality platelet count less 100,000/ul , ANC less 1000/ul 10 . Donor history Crohn 's ulcerative colitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>